Additional file 1: of Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Figure S1. Ratio of cleaved:total cytokeratin 18 (M30/M65 ELISA assay) in patients treated with weekly ONC201. Figure S2. Maximum fold change over baseline of immune cytokines and effector molecules in all ONC201-treated patients in the two dosing cohorts (every three weeks and weekly dosing schedules). Figure S3. (A) Maximum fold change of serum prolactin levels in the serum relative to baseline when compared to maximum concentration of ONC201 in the serum of the patients treated on a weekly schedule. Figure S4. Maximum fold induction of caspase-cleaved cytokeratin 18 levels in the serum relative to baseline when compared to maximum concentration of ONC201 in the serum of the patients treated on a weekly schedule. Figure S5. Timing of maximum fold-induction of immune cytokines and effects. Figure S6. Serum PSA (ng/mL) of ONC201-treated prostate cancer patients. Table S1. Treatment-related adverse events (AEs) in patients treated with ONC201 on a weekly schedule. Table S2. Pharmacokinetic parameters for 625 mg of ONC201 after the first dose of cycle 1 and after the first dose of cycle 2 (n = 17). (DOCX 324 kb)